Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
MYELODYSPLASTIC SYNDROME AND ACUTE MYELOGENOUS LEUKEMIA AS A LATE CLONAL COMPLICATION IN CHILDREN WITH ACQUIRED APLASTIC-ANEMIA
Autore:
OHARA A; KOJIMA S; HAMAJIMA N; TSUCHIDA M; IMASHUKU S; OHTA S; SASAKI H; OKAMURA J; SUGITA K; KIGASAWA H; KIRIYAMA Y; AKATSUKA J; TSUKIMOTO I;
Indirizzi:
TOHO UNIV,SCH MED,DEPT PEDIAT 1,OTA KU,6-11-1 OMORI NISHI TOKYO 143 JAPAN JAPANESE SOC PEDIAT HEMATOL,APLAST ANEMIA COMM TOKYO JAPAN
Titolo Testata:
Blood
fascicolo: 3, volume: 90, anno: 1997,
pagine: 1009 - 1013
SICI:
0006-4971(1997)90:3<1009:MSAAML>2.0.ZU;2-5
Fonte:
ISI
Lingua:
ENG
Soggetto:
COLONY-STIMULATING FACTOR; SAA WORKING PARTY; BONE-MARROW TRANSPLANTATION; ANTILYMPHOCYTE GLOBULIN; CONGENITAL NEUTROPENIA; ANTITHYMOCYTE GLOBULIN; G-CSF; CYCLOSPORINE; METHYLPREDNISOLONE; IMMUNOSUPPRESSION;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
26
Recensione:
Indirizzi per estratti:
Citazione:
A. Ohara et al., "MYELODYSPLASTIC SYNDROME AND ACUTE MYELOGENOUS LEUKEMIA AS A LATE CLONAL COMPLICATION IN CHILDREN WITH ACQUIRED APLASTIC-ANEMIA", Blood, 90(3), 1997, pp. 1009-1013

Abstract

The improved outcome of acquired aplastic anemia (AA) has revealed later complications, such as myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML). We retrospectively analyzed 167 children with severe acquired AA, Eleven of 50 children treated with cyclosporin (CSA) and recombinant human granulocyte colony-stimulating factor (rhG-CSF) developed MDS/AML; 8 of these were within 36 months of the diagnosis of AA, much earlier than previous reports. Six of the 11 children received rhG-CSF exceeding 10 mu g/kg/d, and 9 received rhG-CSF therapy for over 1 year, Ten children showed monosomy 7 at diagnosis of MDS,All of the 11 children were administered both CSA and rhG-CSF. There was no development of MDS/AML among 41 children treated with either CSA or rhG-CSF or among 48 children who underwent bone marrow transplantation. A well-controlled clinical trial is warranted to determine whether therapeutic modalities affect the development of MDS/AML in children with severe acquired AA. (C) 1997 by The American Society of Hematology.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 09/04/20 alle ore 20:05:22